Skip to main content
. Author manuscript; available in PMC: 2008 Mar 18.
Published in final edited form as: Hum Gene Ther. 2007 Mar;18(3):269–285. doi: 10.1089/hum.2006.186

Table 1. Correction of anemia in a rat disease model by the repeated, small-dose injections of mMCK-ratEPO.

The anemia model was created as described for Figure 3. The Δ Hct values that were graphically illustrated on Fig. 3C are here presented in a table format for Groups 3–6, along with the p-values of the statistical analysis comparing these groups. The cumulative Empty-mMCK control and mMCK-RhEPO pDNA doses delivered by day 133, 168 and 203 are also shown. The last column reflects the maximum increase in hematocrit values in each group relative to the total amount of delivered plasmid DNA (Δ Hct/μg DNA).

The additive effect of repeated small-dose injections on hematocrit changes in a rat model of anemia
Weeksa 0 1 4 8 Cumulative 9 10 13 Cumulative 14 15 16 18 Cumulative Total gain:
max
Group Injected
DNA
Daysb 84 105 133 DNA dose 147 168 DNA dose 182 189 203 DNA dose Δ Hct/μg DNA

3 Empty-mMCK control Δ Hct vs Day 63 1st injection on Day 77 0.8 3.5 2.7 50 μg Ctr. 2nd injection on Day 140 −1.5 0.7 75 μg Ctr. 3rd injection on Day 175 −2.2 −2.1 −3.5 100 μg Ctr. 0.035
4 25+25+25 μg mMCK-ratEPO ΔHct vs Day 63 2.7 7.7 8.1 25 μg 4.7 9.9 50 μg 13.6 14.4 16.5 75 μg 0.220
5 50+25 μg mMCK-ratEPO Δ Hct vs Day 63 4.0 10.2 12.0 50μg 11.2 14.2 75μg 13.0 15.1 15.7 100 μg 0.157
6 100 μg mMCK-ratEPO Δ Hct vs Day 63 5.7 15.5 17.8 100 μg 15.9 15.3 100 μg 13.5 15.6 12.4 100 μg 0.178

Probability (p) values for the pairwise comparison of EPO-treated and control groups using Analysis of Variance (ANOVA)

3 vs 4 0.016 0.018 0.000 0.000
3 vs 5 0.000 0.000 0.000 0.000
3 vs 6 0.000 0.000 0.000 0.003
4 vs 5 0.142 0.107 0.108 0.730
4 vs 6 0.000 0.000 0.058 0.254
5 vs 6 0.004 0.015 0.727 0.458
a

Weeks are counted from the time of the 1 st DNA injections.

b

Days are counted from the time of drawing the first blood samples before initiating the study.